Anika Therapeutics ANIK Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's additional paid-in capital?
- Anika Therapeutics (ANIK) reported additional paid-in capital of $83.35M in Q1 2026.
- How has Anika Therapeutics's additional paid-in capital changed year-over-year?
- Anika Therapeutics's additional paid-in capital decreased by 4.8% year-over-year, from $87.56M to $83.35M.
- What is the long-term trend for Anika Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Anika Therapeutics's additional paid-in capital has grown at a 9.6% compound annual growth rate (CAGR), from $55.36M to $87.5M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.